Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cebranopadol TQT Study
NCT03958123Phase 1Completed
- Sponsor
- Tris Pharma
- Start
- Jul 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cebranopadol in chronic pain (4 arms), sponsored by Tris Pharma. Primary endpoint: QTcNi change from time-matched baseline measurement at Day 29. Started Jul 2013; status: completed.
02
Drugs
cebranopadol
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT03958123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958123.